- Home
- SDOT vs SYBX Comparison
SDOT vs SYBX Comparison
Compare SDOT & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDOT
- SYBX
- Stock Information
- Founded
- SDOT 2014
- SYBX N/A
- Country
- SDOT United States
- SYBX United States
- Employees
- SDOT N/A
- SYBX N/A
- Industry
- SDOT Restaurants
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- SDOT Consumer Discretionary
- SYBX Health Care
- Exchange
- SDOT Nasdaq
- SYBX Nasdaq
- Market Cap
- SDOT N/A
- SYBX 13.6M
- IPO Year
- SDOT 2020
- SYBX N/A
- Fundamental
- Price
- SDOT $1.31
- SYBX $1.18
- Analyst Decision
- SDOT
- SYBX
- Analyst Count
- SDOT 0
- SYBX 0
- Target Price
- SDOT N/A
- SYBX N/A
- AVG Volume (30 Days)
- SDOT 30.1K
- SYBX 7.8K
- Earning Date
- SDOT 05-19-2025
- SYBX 05-13-2025
- Dividend Yield
- SDOT N/A
- SYBX N/A
- EPS Growth
- SDOT N/A
- SYBX N/A
- EPS
- SDOT 0.85
- SYBX N/A
- Revenue
- SDOT $700,937,000.00
- SYBX $8,000.00
- Revenue This Year
- SDOT $12.76
- SYBX N/A
- Revenue Next Year
- SDOT $5.54
- SYBX N/A
- P/E Ratio
- SDOT $1.53
- SYBX N/A
- Revenue Growth
- SDOT N/A
- SYBX N/A
- 52 Week Low
- SDOT $1.33
- SYBX $0.90
- 52 Week High
- SDOT $7.00
- SYBX $1.91
- Technical
- Relative Strength Index (RSI)
- SDOT 22.03
- SYBX 52.96
- Support Level
- SDOT $1.51
- SYBX $1.07
- Resistance Level
- SDOT $1.48
- SYBX $1.19
- Average True Range (ATR)
- SDOT 0.13
- SYBX 0.08
- MACD
- SDOT -0.00
- SYBX 0.01
- Stochastic Oscillator
- SDOT 7.36
- SYBX 88.89
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.